Abstract
The recurrence risk for advanced ovarian cancer managed using surgical cytoreduction and adjuvant chemotherapy is 60% to 70% [1]. The standard treatment of recurrent disease is still under debate and depends on patient history and characteristics of the tumor [1,2]. Recently, the role of cytoreductive surgery for platinum-sensitive cancer has been reassessed, and findings indicate that residual tumor is the most valuable determining factor for survival, even in recurrent disease [3]. Preliminary data seem to demonstrate that the addition of hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) could improve overall survival in these patients [4,5].
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
